27 December 2021 - - Israeli generic and specialty pharmaceutical company Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) (TASE: TEVA) Teva Pharmaceuticals US affiliate has launched a first-to-market generic version of Narcan1 (naloxone hydrochloride nasal spray), in the United States, the company said.

Naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness or not being able to respond.

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US.

Currently, 1 in 12 generic prescriptions dispensed in the US is filled with a Teva generic product.